• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Tamiflu May Thwart Pneumonia in 'Swine Flu' Patients: Study

tetano

Editor, Senior Moderator
TUESDAY, Sept. 28 (HealthDay News) -- When taken shortly after the onset of symptoms, the antiviral drug Tamiflu seems to have protected otherwise healthy swine flu patients from contracting pneumonia during the 2009 H1N1 pandemic, Chinese researchers say.

Tamiflu may also have shortened the period that patients were contagious and reduced the duration of their fevers, the research team said.

However, reporting in the Sept. 29 issue of bmj.com, the study authors stressed that their findings should be interpreted with caution given that the conclusions are based on an after-the-fact analysis and on a pool of patients not uniformly given chest X-rays at the time of illness.

The study team, led by Dr. Weizhong Yang and Dr. Hongjie Yu from the Chinese Center for Disease Control and Prevention in Beijing, note that in 2009 the fast-spreading influenza A (H1N1) virus killed more than 18,000 people in over 200 countries.

Prior research has suggested that patients who take antiviral medications within two days of experiencing seasonal flu symptoms may develop a less severe and shorter-lasting illness and may also reduce their risk for complications.

To gauge to what degree this might be true for healthy patients with a mild form of H1N1, the research team reviewed the medical records of nearly 1,300 Chinese patients diagnosed with the infection in 2009.

The average age of the patients was 20. More than three-quarters were given Tamiflu within a median of three days following the onset of symptoms, and 920 of the patients underwent follow-up chest X-rays.

Just 12 percent of those X-rayed had signs of pneumonia, the researchers observed. None of them needed admission for intensive care, and none required mechanical ventilation.

Even after accounting for age, gender, influenza vaccine and antibiotic treatment history, the authors concluded that Tamiflu treatment appeared to offer significant protection against pneumonia.

This protective effect was apparent in all patients who took Tamiflu, even those who took it more than 48 hours after symptom onset, but those who took the medication within 48 hours experienced shorter fevers and were contagious for a shorter time.

The Chinese team nonetheless called for more follow-up research to investigate the potential benefits of Tamiflu for swine flu.

http://www.businessweek.com/lifestyle/content/healthday/643646.html
 
BMJ. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China

BMJ. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China

Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1... (BMJ, abstract, edited)


[Source: BMJ, free full text: <cite cite="http://www.bmj.com/content/341/bmj.c4779.full">Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China -- Yu et al. 341 -- bmj.com</cite>. Abstract, edited.]

BMJ 2010; 341:c4779 doi: 10.1136/bmj.c4779 (Published 28 September 2010)
Cite this as: BMJ 2010; 341:c4779

Research

Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China

This article has been Unlocked
Free via Creative Commons: OPEN ACCESS

1. Hongjie Yu, medical epidemiologist/deputy director 1, 2. Qiaohong Liao, public health officer 1, 3. Yuan Yuan, respiratory physician 2, 4. Lei Zhou, public health officer 1, 5. Nijuan Xiang, public health officer 1, 6. Yang Huai, public health officer 1, 7. Xiuhua Guo, professor 3, 8. Yingdong Zheng, associate professor 4, 9. H Rogier van Doorn, clinical microbiologist 5, 10. Jeremy Farrar, professor 5, 11. Zhancheng Gao, professor/respiratory physician 2, 12. Zijian Feng, medical epidemiologist/director 1, 13. Yu Wang, professor/director 6, 14. Weizhong Yang, medical epidemiologist/deputy director 6

Author Affiliations

1. 1Office for Disease Control and Emergency Response, Chinese Centre for Disease Control and Prevention, Beijing, China
2. 2Department of Respiratory Internal Medicine, Peking University People?s Hospital, Peking University Health Science Centre, Beijing
3. 3School of Public Health and Family Medicine, Capital Medical University, Beijing
4. 4School of Public Health, Peking University Health Science Centre, Beijing
5. 5Oxford University Clinical Research Unit, South East Asia Infectious Diseases Clinical Research Network, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
6. 6Chinese Centre for Disease Control and Prevention, Beijing

1. Correspondence to: W Yang yangwz@chinacdc.cn and H Yu yuhj@chinacdc.cn, Chinese Centre for Disease Control and Prevention, 155 Changbai Road, Changping District, Beijing, 102206, People?s Republic of China

Accepted 28 June 2010


Abstract

Objective
To describe the clinical features and effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A(H1N1) virus infection.

Design
Opportunistic retrospective review of medical charts of patients with confirmed 2009 H1N1 identified through the national surveillance system in China from May to July 2009.

Setting
Under coordination of the Ministry of Health, local health departments were asked to collect medical records of confirmed patients and send them to the Chinese Centre for Disease Control and Prevention on a voluntary basis as part of the public health response.

Population
1291 patients with confirmed 2009 H1N1 infection and available data for chart review.

Main outcome measures
Demographic characteristics, comorbidities, symptoms and signs, laboratory tests, findings on chest radiography, antiviral treatment, duration of fever, and duration of viral RNA shedding.

Results
The median age of 1291 patients was 20 years (interquartile range 12-26); 701 (54%) were male. The most common symptoms were fever (820, 64%), cough (864, 67%), sore throat (425, 33%), sputum (239, 19%), and rhinorrhoea (228, 18%). Of 920 patients who underwent chest radiography, 110 (12%) had abnormal findings consistent with pneumonia. Some 983 (76%) patients were treated with oseltamivir from a median of the third day of symptoms (2-4). No patients required admission to the intensive care unit or mechanical ventilation. 2009 H1N1 was shed from one day before onset of symptoms to up to eight days after onset in most (91%) patients, with a median of 5 (3-6) days of shedding after onset. Treatment with oseltamivir significantly protected against subsequent development of radiographically confirmed pneumonia (odds ratio 0.12, 95% confidence interval 0.08 to 0.18), and treatment started within two days of symptom onset reduced the duration of fever and viral RNA shedding.

Conclusions
Chinese patients with 2009 H1N1 infection predominantly presented with features of uncomplicated, self limiting acute respiratory illness. 2009 H1N1 might be shed longer than seasonal influenza virus. Treatment with oseltamivir was associated with a significantly reduced development of radiographically confirmed pneumonia and a shorter duration of fever and viral RNA shedding. Though these patients benefited from treatment, the findings should be interpreted with caution as the study was retrospective and not all patients underwent chest radiography.

-
-------
 
Back
Top Bottom